Ampio to study experimental drug in COVID-19 patients

U.S. drug developer Ampio Pharmaceuticals Inc said on Friday it would begin an early stage study of its experimental treatment, Ampion, in COVID-19 patients after it received regulatory clearance from the U.S. Food and Drug Administration.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.